Phase I/II study of irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI) in Japanese patients with advanced colorectal cancer and genetic testing for UDP-glucuronosyltransferase (UGT) 1A1*28 and *6.
| Project/Area Number |
20590546
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
NAGASHIMA Fumio Saitama Medical University, 医学部, 客員准教授 (70348209)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SASAKI Yasutsuna 埼玉医科大学, 医学部, 教授 (20235279)
FUJITA Keniti 埼玉医科大学, 医学部, 講師 (60281820)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2010: ¥130,000 (Direct Cost: ¥100,000、Indirect Cost: ¥30,000)
Fiscal Year 2009: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2008: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
|
|---|
| Keywords | ヒト組織利用研究 / 臨床薬理学 / ゲノム薬理学 / イリノテカン / UGT1A1 / 薬物動態 / 遺伝子多型 / 個別化医療 / 大腸癌 / 副作用 / 塩酸イリノテカン / 用量調節試験 / UGTIA1 / ABCC2 |
|---|
| Research Abstract |
This phase I/II study demonstrates that the recommended doses of irinotecan and infusional 5-fluorouracil in FOLFIRI for Japanese patients with advanced colorectal cancer who do not possess the UDP-glucuronosyltransferase 1A1*28 allele are 180 and 2400mg/m^2, respectively. Toxicities occurring at the recommended doses are manageable in these patients.
|
Report
(4 results)
Research Products
(25 results)
-
[Journal Article] Phase I/II study of FOLFIRI in Japanese patients with advanced colorectal cancer.2011
Author(s)
Yamashita K, Nagashima F, Fujita K, Yamamoto W, Endo H, Miya T, Narabayashi M, Kawara K, Akiyama Y, Ando Y, Ando M, Sasaki Y.
-
Journal Title
Jpn J Clin Oncol 41
Pages: 204-209
Related Report
Peer Reviewed
-
-
-
[Journal Article] UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.2010
Author(s)
Sunakawa Y, Ichikawa W, Fujita KI, Nagashima F, Ishida H, Yamashita K, Mizuno K, Miwa K, Kawara K, Akiyama Y, Araki K, Yamamoto W, Miya T, Narabayashi M, Ando Y, Hirose T, Saji S, Sasaki Y.
-
Journal Title
Cancer Chemother Pharmacol in press
Related Report
-
-
-
-
[Journal Article] Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI).2008
Author(s)
Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Matsunaga M, Araki K, Tanaka R, Ichikawa W, Miya T, Narabayashi M, Akiyama Y, Kawara K, Ando Y, Sasaki Y.
-
Journal Title
Biol Pharm Bull 31
Pages: 2137-2142
NAID
Related Report
Peer Reviewed
-
[Journal Article] Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.2008
Author(s)
Akiyama Y, Fujita K, Nagashima F, Yamamoto W, Endo H, Sunakawa Y, Yamashita K, Ishida H, Mizuno K, Araki K, Ichikawa W, Miya T, Narabayashi M, Kawara K, Sugiyama M, Hirose T, Ando Y, Sasaki Y.
-
Journal Title
Ann Oncol 19
Pages: 2089-2090
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Book] 個別化医療2011
Author(s)
長島文夫
Total Pages
320
Publisher
株式会社技術情報協会
Related Report
-
-
